Diabetic Retinopathy Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Diabetes to Drive Market Growth
- Rising Technological Advancements Associated with Diabetic Retinopathy Treatment to Expand Market
Challenges
- Lack of Trained Ophthalmologists in Low Income Economies Restraining Market Growth
Diabetic Retinopathy Market: Key Insights
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6.5% |
|
Base Year Market Size (2023) |
USD 8.91 billion |
|
Forecast Year Market Size (2036) |
USD 20.2 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of diabetic retinopathy is estimated at USD 10.01 billion.
Diabetic Retinopathy Market size was valued at USD 9.49 billion in 2024 and is set to exceed USD 21.52 billion by 2037, expanding at over 6.5% CAGR during the forecast period i.e., between 2025-2037.
North America industry is estimated to account for largest revenue share by 2037, driven by supportive reimbursement policies covering treatment costs, sophisticated healthcare infrastructure, and allocation of substantial healthcare expenditure by government.
The major players in the market are Pfizer Inc. Bayer AG, Abbott Laboratories, Novartis AG, and others.
